Implementation of universal screening for preterm delivery by mid-trimester cervical-length measurement.
Administration, Intravaginal
Adolescent
Adult
Cervical Length Measurement
/ instrumentation
Cervix Uteri
/ anatomy & histology
Cross-Sectional Studies
Feasibility Studies
Female
Humans
Incidence
Mass Screening
/ methods
Middle Aged
Predictive Value of Tests
Pregnancy
Pregnancy Trimester, Second
Premature Birth
/ diagnostic imaging
Progesterone
/ administration & dosage
Progestins
/ therapeutic use
Retrospective Studies
Ultrasonography
/ methods
Young Adult
cervix
preterm delivery
progesterone
second trimester
transvaginal ultrasound
Journal
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
ISSN: 1469-0705
Titre abrégé: Ultrasound Obstet Gynecol
Pays: England
ID NLM: 9108340
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
09
09
2017
revised:
05
03
2018
accepted:
05
03
2018
pubmed:
15
3
2018
medline:
3
5
2019
entrez:
15
3
2018
Statut:
ppublish
Résumé
To assess the feasibility and results of introducing a policy of universal screening for preterm delivery (PTD) by mid-trimester cervical-length (CL) measurement. In this retrospective cross-sectional study of singleton pregnancies, transvaginal sonography for CL measurement was performed at 20-24 weeks of gestation. Vaginal progesterone therapy was offered to women with CL ≤ 15 mm. The incidence of spontaneous PTD (sPTD) according to CL and the distribution of CL measurements were assessed. Rate of PTD before implementation of screening was compared with that after. A total of 10 506 singleton pregnancies were assessed. The decline rate was 1.32%. sPTD < 32 weeks, < 34 weeks and < 37 weeks occurred in 0.51%, 0.82% and 3.90% of pregnancies, respectively. CL measurement was best described by a mixture model distribution comprising a 'short' and a 'long' component. The percentage of the two components varied between subgroups of PTD, with the short component being greater the earlier the birth. CL, history of miscarriage, smoking status and prior PTD were independent predictors in the construction of a model predictive of PTD < 34 weeks (area under the curve = 0.74, P < 0.001). The rate of sPTD < 34 weeks in women with CL ≤ 15 mm receiving progesterone treatment was 20.4%. In the progesterone-treated group, a plateau was observed in the increase in risk for PTD for CL 9-13 mm, whereas below 9 mm the risk increased exponentially. Following the introduction of mid-trimester CL measurement, there was a trend for reduction in the rate of any PTD < 34 weeks of about 20% in comparison with the prescreening period (odds ratio = 0.81; 95% CI, 0.59-1.13). Universal screening for PTD by transvaginal sonographic measurement of CL at 20-24 weeks is feasible and well accepted by pregnant women. This policy identifies a very high-risk group that may benefit from intervention. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
Substances chimiques
Progestins
0
Progesterone
4G7DS2Q64Y
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-401Informations de copyright
Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.